MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/dmrr.3777

Медицинская библиотека · Diabetes/metabolism research and reviews · 2024

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes.

Hendriks A Emile J, Marcovecchio M Loredana, Besser Rachel E J, Bonifacio Ezio, Casteels Kristina, Elding Larsson Helena, Gemulla Gita, Lundgren Markus, Kordonouri Olga, Mallone Roberto, Pociot Flemming, Szypowska Agnieszka, Toppari Jorma, Berge Thekla von dem, Ziegler Anette G, Mathieu Chantal, Achenbach Peter, INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/AIM: Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta-cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody-positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis.

METHODS

Expert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow-up strategies.

RESULTS

The guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3-monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented.

CONCLUSIONS

As type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.

Для цитирования: Hendriks A Emile J, Marcovecchio M Loredana, Besser Rachel E J, Bonifacio Ezio, Casteels Kristina, Elding Larsson Helena, Gemulla Gita, Lundgren Markus, Kordonouri Olga, Mallone Roberto, Pociot Flemming, Szypowska Agnieszka, Toppari Jorma, Berge Thekla von dem, Ziegler Anette G, Mathieu Chantal, Achenbach Peter, INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes.. Diabetes/metabolism research and reviews. 2024. DOI: 10.1002/dmrr.3777.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.